Why GLP-1 weight loss plateaus, and what the trials actually show

What the GLP-1 weight curve actually looks like

Public discussion treats GLP-1 weight loss as a steady decline, but the registration trials show something different. STEP-1 (semaglutide 2.4 mg weekly) reported a mean weight reduction of about 14.9 percent over 68 weeks, with most loss accruing in the first 40 to 60 weeks before flattening . SURMOUNT-1 (tirzepatide 5, 10, and 15 mg weekly) showed a similar shape, reaching roughly 20.9 percent at the 15 mg dose by 72 weeks before slowing .

In other words, the curve is steep, then bends. The bend is the plateau. It is reproducible across compounds, doses, populations, and trial designs, which is the first clue that biology is doing the bending, not behavior.

The receptor side of the story

GLP-1 receptor agonists slow gastric emptying, blunt postprandial glucose excursions, and act on hypothalamic and brainstem circuits that reduce appetite. Sustained agonist exposure shifts receptor density and downstream signaling. Preclinical work has documented homologous desensitization at the GLP-1 receptor, and the GIP component of dual agonists like tirzepatide adds a second pathway that may delay or partially offset that adaptation .

Higher-affinity or multi-receptor compounds (the GLP-1 / GIP / glucagon triple agonist retatrutide is the current example) push the curve further before bending . That is consistent with a model where the plateau is partly a ceiling on the appetite-suppression circuit being engaged at any given dose.

The energy expenditure side

Weight loss of any kind reduces resting energy expenditure beyond what fat-free mass alone would predict, a phenomenon called adaptive thermogenesis. This effect has been documented across diet, surgery, and pharmacologic weight loss, and it does not appear to be unique to GLP-1 therapy .

The practical implication is that the calorie deficit shrinks as weight falls. If energy intake also drifts upward as appetite suppression partially desensitizes, the deficit collapses and the curve flattens. The plateau is the predictable equilibrium, not a failure of the drug.

What actually changes the curve

Three levers have published evidence behind them. First, increasing dose within the labeled range delays the bend, as seen in the dose-response shape of SURMOUNT-1 . Second, adding amylin signaling (cagrilintide, tested as CagriSema) extends weight loss in phase trials by complementing GLP-1 effects on satiety . Third, resistance training and adequate protein intake during loss appear to preserve fat-free mass, which keeps resting expenditure higher than it would otherwise drop.

• Dose escalation within label, with attention to nausea and the FDA dosing-error guidance for compounded products .
• Combination strategies with amylin or glucagon-receptor activity in development pipelines .
• Resistance training plus protein-forward eating during the active loss phase, which is mechanism-grounded but still being formally trialed against GLP-1 backdrops.

What this means for people using these drugs

The plateau is information. It tells you the drug has reached the equilibrium your current dose, training, and intake support. It is not a verdict on adherence and it is not, by itself, a reason to escalate beyond label without a prescriber. The risk profile of compounded GLP-1 products is also different from labeled products, and the FDA has issued repeated cautions on dosing errors with compounded semaglutide and tirzepatide .